Neuraly
7 articles about Neuraly
-
Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson’s Disease
4/19/2022
Neuraly today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD).
-
Neuraly Announces Strategic Sponsored Research Agreement with the University of Pennsylvania to Explore use of NLY01 to Therapeutically Target a Neuroinflammatory Mechanism of Glaucoma
11/10/2020
Study recently published by Penn team in Cell Reports provides evidence that NLY01 has the potential for clinical use in the treatment of glaucoma and potentially other retinal diseases
-
Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease
11/2/2020
Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death
-
CORRECTING and REPLACING Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease
3/3/2020
Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death
-
D&D Pharmatech Raises $137.1M in Series B Financing to Advance Potential Disease-Modifying Treatments
8/14/2019
D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, and parent company of U.S.-based Neuraly Inc., Precision Molecular, Inc. and Theraly Fibrosis Inc., announced that it has completed a $137.1 million Series B round of financing from U.S. and Korean investors.
-
Startup Neuraly Raises $36M to Bring Potential Disease-Modifying Treatments to Patients with Parkinson’s Disease
7/18/2018
Research published in Nature Medicine demonstrates protection against dopamine loss and behavioral deficits associated with Parkinson’s disease
-
Maryland-based Neuraly surged forth from the startup gate with $36 million in Series A funding that will finance the company’s research into the development of therapies for neurodegenerative disorders.